The failure of CervoMed’s much-anticipated RewinD-LB Phase IIb study of neflamapimodin in patients with dementia with Lewy bodies (DLB) has left investors disappointed and the company scratching its head.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?